[{"x_label":"Diffuse hemispheric glioma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 28)","specimen_descriptor_fill":"Pediatric Primary Tumors","box_sample_count":22,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Diffuse hemispheric glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.06,"TPM_sd":7.72,"TPM_min":0.87,"TPM_25th_percentile":2.4,"TPM_median":3.37,"TPM_75th_percentile":4.44,"TPM_max":38.48},{"x_label":"Diffuse hemispheric glioma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 28)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":6,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Diffuse hemispheric glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":0.7,"TPM_sd":0.56,"TPM_min":0.15,"TPM_25th_percentile":0.34,"TPM_median":0.64,"TPM_75th_percentile":0.8,"TPM_max":1.71},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":152,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.81,"TPM_sd":1.37,"TPM_min":0.19,"TPM_25th_percentile":0.97,"TPM_median":1.52,"TPM_75th_percentile":2.17,"TPM_max":9.49},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.65,"TPM_sd":0.83,"TPM_min":0.25,"TPM_25th_percentile":1.14,"TPM_median":1.31,"TPM_75th_percentile":2.37,"TPM_max":3.34},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":507,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.03,"TPM_sd":1.34,"TPM_min":0.07,"TPM_25th_percentile":0.35,"TPM_median":0.57,"TPM_75th_percentile":1.08,"TPM_max":11.25},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.57,"TPM_sd":1.6,"TPM_min":0.29,"TPM_25th_percentile":0.61,"TPM_median":1.16,"TPM_75th_percentile":1.49,"TPM_max":5.78},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":373,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.98,"TPM_sd":1.37,"TPM_min":0.23,"TPM_25th_percentile":1.06,"TPM_median":1.63,"TPM_75th_percentile":2.49,"TPM_max":11.78},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.46,"TPM_sd":1.11,"TPM_min":0.26,"TPM_25th_percentile":0.76,"TPM_median":1.34,"TPM_75th_percentile":1.75,"TPM_max":3.17},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":258,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.52,"TPM_sd":3.04,"TPM_min":0.05,"TPM_25th_percentile":1.57,"TPM_median":2.5,"TPM_75th_percentile":4.62,"TPM_max":18.43},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.6,"TPM_sd":2.19,"TPM_min":3.29,"TPM_25th_percentile":3.33,"TPM_median":3.38,"TPM_75th_percentile":5.25,"TPM_max":7.12}]